Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Survey of amniocentesis for fetal sex determination in hemophilia carriers

Survey of amniocentesis for fetal sex determination in hemophilia carriers A study was designed to determine whether there is an increased risk of complications when amniocentesis for fetal sex determination is performed on hemophilia carriers. Questionnaires were sent to 112 medical centers providing this service in the United States, and to 19 outside the United States. Responses were received from 76 % of the centers in the United States. Data on 11,819 taps were obtained. Only 75 taps (0.64%) were performed for the indication of hemophilia. The frequency of fetal deaths in the general sample (1.84 %) was not significantly different from that in the subsample of hemophilia carriers (1.33 %). The results of this survey correspond very closely to data from a National Registry on amniocentesis for various indications in such variables as the number of taps needed for diagnosis, color of the fluid obtained, and number of dry taps. Carrier women who had bleeding problems during the monitored pregnancy are described. The problems might have been related to the amniocentesis in three women. It is calculated that only 2–4 % of hemophilia carrier women who might have amniocentesis are utilizing the service. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Genetics Wiley

Survey of amniocentesis for fetal sex determination in hemophilia carriers

Loading next page...
 
/lp/wiley/survey-of-amniocentesis-for-fetal-sex-determination-in-hemophilia-Yst2VgnKha

References (10)

Publisher
Wiley
Copyright
1976 Blackwell Munksgaard
ISSN
0009-9163
eISSN
1399-0004
DOI
10.1111/j.1399-0004.1976.tb00058.x
Publisher site
See Article on Publisher Site

Abstract

A study was designed to determine whether there is an increased risk of complications when amniocentesis for fetal sex determination is performed on hemophilia carriers. Questionnaires were sent to 112 medical centers providing this service in the United States, and to 19 outside the United States. Responses were received from 76 % of the centers in the United States. Data on 11,819 taps were obtained. Only 75 taps (0.64%) were performed for the indication of hemophilia. The frequency of fetal deaths in the general sample (1.84 %) was not significantly different from that in the subsample of hemophilia carriers (1.33 %). The results of this survey correspond very closely to data from a National Registry on amniocentesis for various indications in such variables as the number of taps needed for diagnosis, color of the fluid obtained, and number of dry taps. Carrier women who had bleeding problems during the monitored pregnancy are described. The problems might have been related to the amniocentesis in three women. It is calculated that only 2–4 % of hemophilia carrier women who might have amniocentesis are utilizing the service.

Journal

Clinical GeneticsWiley

Published: Nov 1, 1976

There are no references for this article.